A combined stem-cell–gene therapy strategy for ALS
Author:
- 12 September 2022
- journal article
- editorial
- Published by Springer Nature in Nature Medicine
- Vol. 28 (9) , 1751-1752
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trialNature Medicine, 2022
- iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disordersCell Stem Cell, 2022
- Transplantation of Neural Progenitor Cells Expressing Glial Cell Line-Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral SclerosisStem Cells, 2018
- Patients with ALS show highly correlated progression rates in left and right limb musclesNeurology, 2017
- Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degenerationExperimental Neurology, 2008
- GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALSPLOS ONE, 2007
- GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALSHuman Gene Therapy, 2005
- GDNF: a Potent Survival Factor for Motoneurons Present in Peripheral Nerve and MuscleScience, 1994
- GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic NeuronsScience, 1993